Colin Hessel

Colin Hessel has over two decades of experience in the biostatistics and drug development field. Colin has held various leadership positions in companies such as Ambrx, Exelixis, Telik, MedImmune, and Amgen. Their expertise includes study design, protocol development, statistical oversight, and clinical trial execution, particularly in the field of solid tumor oncology. Colin has contributed significantly to successful drug development strategies, clinical trial designs, and FDA approvals in the industry.

Colin Hessel completed a Bachelor of Science (BS) and Bachelor of Arts (BA) in Biology and Political Science at UC Irvine from 1987 to 1992. Colin then went on to earn a Master of Science (MS) in Epidemiology and Applied Statistics from the Keck School of Medicine of the University of Southern California from 1994 to 1996.